Clinical Trial Update: Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the combination of ibrutinib and blinatumomab for relapsed or refractory B-cell acute lymphoblastic leukemia, including Philadelphia ch…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• BLINCYTO (BLINATUMOMAB)
• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: University of California, Davis | Conditions: Adult B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive | Phase 2 | Status: COMPLETED